UBS Starts SAB Biotherapeutics (SABS) at Buy Jan 7, 2026 01:01AM
SAB Biotherapeutics (SABS) files $300M mixed shelf Dec 30, 2025 10:11AM
SAB Biotherapeutics establishes $75 million at-the-market offering program Dec 29, 2025 04:02PM
Guggenheim Starts SAB Biotherapeutics (SABS) at Buy, PT $15 Dec 19, 2025 06:19AM
SAB Biotherapeutics (SABS) files for up to 250M share offering by selling stockholders Sep 22, 2025 05:18PM


Sep 22, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on SAB Biotherapeutics (SABS)
Sep 17, 2025 06:05AM Leerink Partners Starts SAB Biotherapeutics (SABS) at Outperform
Aug 8, 2025 08:23AM SAB Biotherapeutics (SABS) PT Lowered to $12 at Chardan Capital Markets
Jul 22, 2025 06:11AM SAB Biotherapeutics (SABS) PT Lowered to $9 at H.C. Wainwright
Jul 21, 2025 04:37PM SAB Biotherapeutics (SABS) PT Raised to $14 at Oppenheimer
Apr 1, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on SAB Biotherapeutics (SABS)
Oct 9, 2024 07:20AM Craig-Hallum Starts SAB Biotherapeutics (SABS) at Buy
Sep 12, 2024 06:16AM Oppenheimer Reiterates Outperform Rating on SAB Biotherapeutics (SABS)
Aug 27, 2024 04:03PM Oppenheimer Starts SAB Biotherapeutics (SABS) at Outperform
Aug 9, 2024 07:44AM SAB Biotherapeutics (SABS) Misses Q2 EPS by 79c
Jun 20, 2024 07:20AM SAB Biotherapeutics (SABS) Rebrands as SAB BIO